UB Paderborn / Katalog / Suche / in CDI

1 – 21 von 21

Sortiert nach

Modi-1, anti-citrullinated neoepitope vaccine, alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal, and ovarian cancers: ModiFy phase I/II basket clinical trial—Report after completion of monotherapy dose-finding

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2566-2566

2023

Link zum Volltext

Verfügbarkeit prüfen

REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS9145-TPS9145

2023

Link zum Volltext

Verfügbarkeit prüfen

CD8 T‐cell‐mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer

Neuropathology and applied neurobiology, 2022-02, Vol.48 (2), p.e12755-n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.6082-6082

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8506-8506

2023

Link zum Volltext

Verfügbarkeit prüfen

Melanoma-reactive T cells take up residence

Nature cancer, 2021-03, Vol.2 (3), p.253

2021

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy in metastatic melanoma: When is it safe to stop?

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e21518-e21518

2018

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the impact of infliximab use for the treatment of ipilimumab related diarrhoea on the outcome of patients with advanced melanoma

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.9045-9045

2015

Link zum Volltext

Verfügbarkeit prüfen

The association of T cells with survival in mesothelioma

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7560-7560

2015

Link zum Volltext

Verfügbarkeit prüfen

UK experience of combined BRAF and MEK inhibition with dabrafenib and trametinib (D+T) in the metastatic melanoma (MM) named patient programme

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e21027-e21027

2016

Link zum Volltext

Verfügbarkeit prüfen

A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.6068-6068

2018

Link zum Volltext

Verfügbarkeit prüfen

CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS8586-TPS8586

2018

Link zum Volltext

Verfügbarkeit prüfen

GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.2000-2000

2018

Link zum Volltext

Verfügbarkeit prüfen

Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS9099-TPS9099

2017

Link zum Volltext

Verfügbarkeit prüfen

Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3034-3034

2015

Link zum Volltext

Verfügbarkeit prüfen

Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e20049-e20049

2015

Link zum Volltext

Verfügbarkeit prüfen

UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9542-9542

2016

Link zum Volltext

Verfügbarkeit prüfen

Biomarker for benefit from ipilimumab: Correlation of breadth of humoral tumor-antigen-specific immunity with outcome

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.8566-8566

2012

Link zum Volltext

Verfügbarkeit prüfen

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.9068-9068

2013

Link zum Volltext

Verfügbarkeit prüfen

Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.9050-9050

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7081-7081

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Kollektion

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(19)
Nature Cancer
(1)
Neuropathology And Applied Neurobiology
(1)

Menü

Weitere Dienste

Einstellungen

Modi-1, anti-citrullinated neoepitope vaccine, alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal, and ovarian cancers: ModiFy phase I/II basket clinical trial—Report after completion of monotherapy dose-finding

REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design

CD8 T‐cell‐mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer

Safety and immunogenicity of TG4050: A personalized cancer vaccine in head and neck carcinoma

Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma

Melanoma-reactive T cells take up residence

Immunotherapy in metastatic melanoma: When is it safe to stop?

Evaluation of the impact of infliximab use for the treatment of ipilimumab related diarrhoea on the outcome of patients with advanced melanoma

The association of T cells with survival in mesothelioma

UK experience of combined BRAF and MEK inhibition with dabrafenib and trametinib (D+T) in the metastatic melanoma (MM) named patient programme

A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC)

CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma

GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma

Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II)

Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy

Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse

UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma

Biomarker for benefit from ipilimumab: Correlation of breadth of humoral tumor-antigen-specific immunity with outcome

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma

Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma

Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052

Suchergebnisse filtern